Butyrate Effects on Colorectal Cancer Organoids via HDAC2 Inhibition

A research document from Banghui Liu, last updated May 2026, explores the therapeutic effects of butyrate on colorectal cancer. The study uses CRC organoids derived from KPC mice and Caco-2 cells to examine growth suppression, apoptosis, and cell cycle arrest. Transcriptomic analyses indicate butyrate acts as an epigenetic modulator targeting HDAC2.

Use Cases

• Study the anti-proliferative effects of butyrate based on organoid morphology analysis described.
• Investigate HDAC2 inhibition as a therapeutic pathway based on transcriptomic findings mentioned.
• Model cell cycle arrest in CRC based on cyclin D1, CDK4/6, and p21 expression changes discussed.
• Compare in vitro cell line results with 3D organoid models based on the study's methodological focus.

Strengths

• Focus on 3D organoid models, which the description states better recapitulate tumor characteristics than cell lines.
• Includes transcriptomic analysis to identify molecular targets, specifically HDAC2, as described.
• Employs multiple experimental assays including subcutaneous allografts and selective inhibitor use, as outlined in the methods.

Limitations

• Column-level documentation is absent; field semantics must be inferred after download.
• Row count is unknown, which may limit suitability assessment.
• The 2.1 MB file size suggests a small dataset, likely containing the research document rather than extensive raw data.

Provenance

Source

figshare

Collection Method

Experimental research using CRC organoids derived from KPC mice and Caco-2 cells, as described.

Freshness

Last updated 2026-05-19 05:38:46; freshness should be verified.